Dexcom (DXCM) Invested Capital (2010 - 2025)

Dexcom (DXCM) has reported Invested Capital for 13 consecutive years, with $2.7 billion the latest figure, recorded in Q4 2025.

• On a quarterly basis, Invested Capital fell 16.96% year-over-year to $2.7 billion in Q4 2025; TTM through Dec 2025 was $2.7 billion, a 16.96% decrease from a year earlier, with the FY2025 full-year figure at $2.7 billion, down 16.96% from the prior year.
• Invested Capital was $2.7 billion for Q4 2025 at Dexcom, down from $3.9 billion in the prior quarter.
• Over five years, Invested Capital peaked at $3.9 billion in Q3 2025 and troughed at $2.0 billion in Q4 2021.
• A 5-year average of $3.0 billion and a median of $2.9 billion in 2022 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital dropped 28.78% in 2023 and soared 59.87% in 2024, its largest moves.
• Over 5 years, Invested Capital stood at $2.0 billion in 2021, then jumped by 42.23% to $2.9 billion in 2022, then retreated by 28.78% to $2.1 billion in 2023, then soared by 59.87% to $3.3 billion in 2024, then dropped by 16.96% to $2.7 billion in 2025.
• The last three Invested Capital figures came in at $2.7 billion (Q4 2025), $3.9 billion (Q3 2025), and $3.8 billion (Q2 2025), per Business Quant data.